- Clinical-stage biotechnology firm PharmAust will commence a new Phase 1 clinical trial for evaluating monepantel (MPL).
- New data from Amplia’s pancreatic cancer model demonstrated that AMP945 could improve anticancer activity when administered with the standard of care.
- Actinogen Medical has received Ethics Committee’s approval for the study evaluating treatment for patients suffering from Alzheimer’s Disease.
On Wednesday, ASX 200 closed higher, gaining 75.20 points or 1.05% and setting a new 100-day high record. Among the stocks that did well today, three ASX listed healthcare players - PharmAust Limited (ASX:PAA), Amplia Therapeutics Limited (ASX:ATX) and Actinogen Medical (ASX:ACW) - posted some key updates related to clinical development.
PAA shares ended the day’s trade at A$U0.095, up by 3.260%, while ATX shares last traded at AU$0.280, up by 36.585%. ACW shares last traded closed at AU$0.130 on the ASX, up by 23.809%.
Let us look closely at the updates of PAA, ATX and ACW-
PharmAust receives ethics approval for Phase 1 monepantel trial
Clinical-stage biotechnology firm PharmAust revealed that it would proceed with a new Phase 1 clinical trial for evaluating monepantel (MPL) in patients suffering from ALS/MND (amyotrophic lateral sclerosis/motor neurone disease). The Company stated that the trial would be funded and performed in collaboration with Calvary HealthCare Bethlehem, FightMND, and Macquarie University.
Copyright © 2021 Kalkine Media
PharmAust is confident that monepantel will get orphan drug designation (ODD) by the Food and Drug Administration (FDA) for motor neurone disease in due time. The Company anticipates commencing Phase 1 trial in Q4 CY21.
PAA disclosed that Monash Health Human Research Ethics Committee (HREC) had approved the MPL clinical trial protocol.
Dr Richard Mollard, Chief Scientific Officer of PharmAust, said-
Amplia’s AMP945 improves survival in pancreatic cancer model
The developer of new cancer and fibrosis treatment approaches, Amplia Therapeutics, has received new data for its Focal Adhesion Kinase (FAK) inhibitor AMP945. The data from the pancreatic cancer model demonstrated that AMP945 could improve the anticancer activity of combined gemcitabine and Abraxane® in an animal pancreatic cancer model.
Notably, the addition of AMP945 to the standard of care increases the survival rate by 27% in the pancreatic cancer model. The Company stated that the new data provide further support for the advancement of AMP945 into Phase 2 clinical studies.
Dr John Lambert, CEO of Amplia, stated:
Actinogen obtains Ethics Committee go-ahead for XanaMIA study
A developer of novel therapies for neurological disorders, Actinogen Medical has updated the market with the progression of its clinical development program to treat patients suffering from Alzheimer’s Disease (AD).
The Company revealed that it had obtained approval from the Bellberry Human Research Ethics Committee (HREC) to commence the first part of its XanaMIA study. The study is designed to evaluate the improvements in cognitive ability in older volunteers and patients suffering from Mild Cognitive Impairment (MCI), an early clinical stage of AD.
The Ethics Committee approval allows the enrolment of the first patients, which is anticipated in July 2021.
Actinogen has disclosed that the Company has planned to conduct XanaMIA study will be conducted in two parts-
Copyright © 2021 Kalkine Media (Data Source: ACW Update, 2 June 2021)
The XanaMIA part A Study will evaluate 5mg and 10mg doses of Xanamem® to confirm the minimum effective dose. This Company notified that part A utilises the Cogstate Neurological Test Battery, supplemented by the Digit Symbol Substitution Test that the FDA previously approved.
The XanaMIA part B study will be conducted in a group of patients with Mild Cognitive Impairment due to biomarker positive.